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Abstract
Over the past decade, firefly Luciferase (fLuc) has been used in a wide range of biological assays, providing insight into gene
regulation, protein-protein interactions, cell proliferation, and cell migration. However, it has also been well established that
fLuc activity can be highly sensitive to its surrounding environment. In this study, we found that when various cancer cell
lines (HeLa, MCF-7, and 293T) stably expressing fLuc were treated with staurosporine (STS), there was a rapid loss in
bioluminescence. In contrast, a stable variant of Renilla luciferase (RLuc), RLuc8, exhibited significantly prolonged
functionality under the same conditions. To identify the specific underlying mechanism(s) responsible for the disparate
sensitivity of RLuc8 and fLuc to cellular stress, we conducted a series of inhibition studies that targeted known intracellular
protein degradation/modification pathways associated with cell death. Interestingly, these studies suggested that reactive
oxygen species, particularly hydrogen peroxide (H2O2), was responsible for the diminution of fLuc activity. Consistent with
these findings, the direct application of H2O2 to HeLa cells also led to a reduction in fLuc bioluminescence, while H2O2
scavengers stabilized fLuc activity. Comparatively, RLuc8 was far less sensitive to ROS. These observations suggest that fLuc
activity can be substantially altered in studies where ROS levels become elevated and can potentially lead to ambiguous or
misleading findings.
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Introduction
Bioluminescence is widely considered an attractive platform for
many molecular imaging applications given its sensitivity, cost-
effectiveness, simplicity, high-throughput screening potential and
ability to garner temporal information in cells and in live animal
models. Bioluminescent reporters are regularly used to study the
regulation of gene expression by cis- or trans-acting factors, such as
gene regulatory elements[1], transcription factors[2], or exogenous
regulators[3]. Luciferase enzymes have also been used for tracking
cell migration[4] in living subjects and monitoring intracellular
molecular interactions[5].
Since bioluminescent assays often involve studying the cellular
response to stimulatory and/or death-inducing conditions, lucif-
erase enzymes can often be exposed to harsh intracellular
environments. For example, during apoptosis various proteases
(e.g. caspases[6], cathepsins[7], calpains[8]) can be activated or
released into the cytosol, proteasomal activity can be upregulated
as a result of increased protein ubiquitination[9], and reactive
oxygen species (ROS) can create a state of oxidative stress[10].
Each of these mechanisms can potentially alter or impair
bioluminescent enzyme function and ultimately interfere with
the outcome of reporter gene assays.
To avoid the premature loss of bioluminescent activity,
various bioluminescent proteins have been engineered to
possess increased stability. Some examples include variants of
Firefly luciferase (fLuc) that exhibit increased pH stability and
thermostability up to 45uC [11], have a 3-fold longer half-life
(T1/2) in vivo compared to wild-type fLuc [12], or take up to 10-
fold longer to decay compared to wild-type fLuc [13].
Similarly, a variant of Renilla Luciferase (rLuc), rLuc8, has
been engineered that demonstrates a 200-fold higher resistance
to serum inactivation and a light output that is 4-fold greater
than wild-type rLuc [14]. Given the improved optical
properties of these mutants, one or more of them could be a
more desirable candidate for molecular imaging studies
involving cellular stresses. Consistent with this hypothesis, we
found that RLuc8 was significantly more resistant to inactiva-
tion in apoptotic cells, compared with fLuc (see Results).
Although these findings were not surprising, it remained
unclear which intracellular mechanisms were responsible for
the rapid loss in fLuc activity. To elucidate the root cause for
fLuc inactivation, a series of inhibition studies were conducted
that targeted various intracellular protein degradation/modifi-
cation pathways associated with apoptosis. Surprisingly, these
experiments suggested that ROS, particularly hydrogen perox-
ide (H2O2), were responsible for the loss in fLuc activity.
Notably, RLuc8 was far less sensitive to ROS. These results
were confirmed by subjecting cells, expressing fLuc and RLuc8,
to various conditions that resulted in a specific increase or
decrease in H2O2 levels. Considering the growing data linking
elevated levels of ROS to various pathologies including
atherosclerosis, cancer, cystic fibrosis, type-2 diabetes, and
Alzheimer’s disease, these findings suggest that the use of fLuc
could potentially lead to ambiguous or misleading findings
when applied to these systems.
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RLuc8 is more resistant to inactivation in apoptotic cells,
compared with fLuc, resulting in an increase in the
RLuc8:fLuc bioluminescence ratio
When HeLa cells expressing fLuc and RLuc8 (i.e. HeLa-fR) were
treated with 10 mM staurosporine (STS), a drug that induces
apoptosis[15], the bioluminescent signal from fLuc was significantly
reduced over a time period of 24 hours, while the signal from Rluc8
remained comparatively stable (Figure 1a). This differential
sensitivity to cellular stress can be represented as an increase in
the bioluminescent ratio (Rluc8 activity:fLuc activity), as shown on
the secondary axis in Figure 1a. Representative bioluminescent
images obtained from HeLa-fR cells under the same conditions are
shown in Figure 1b. Little to no increase in the Rluc8:fLuc ratio was
observed in cells that were not treated with STS over the same time
period (Figure S1a). Further, the Rluc8:fLuc ratio was independent
of cell number (Figure S1b). A TUNEL assay confirmed that the
STS-treatment was sufficient to induce cell death over the indicated
time course (Figure 1c) and a caspase-GLOH 3/7 assay (Promega)
confirmed that cell death was caspase-dependent (Figure S2a).
When HeLa-fR cells were treated with increasing doses of STS,
the Rluc8:fLuc ratio and extent of cell death also increased in a
dose-dependent manner (Figure 1d–f and Figure S2b, respective-
ly). Importantly, these findings were not unique to STS-treated
HeLa cells. An increase in the RLuc8:fLuc ratio was also observed
when MCF7 (Figure S3a) and 293T/17 (Figure S3d) cells were
treated with STS. In both cases, cell death was confirmed by
TUNEL assays (Figure S3b and Figure S3e, respectively) and
caspase involvement was confirmed using caspase-GLOH 3/7
(Figure S3c and S3f, respectively).
Although it was not surprising that RLuc8 exhibited prolonged
bioluminescent activity in apoptotic cells, compared with fLuc, it
remained unclear which intracellular mechanism(s) was specifically
responsible for the loss in fLuc activity. Since all measurements of
fLuc and RLuc8 activity that are shown were acquired using the in
vitro assay kit, Dual-Glo (Promega), a lack of ATP, Mg
2+, and
oxygen could immediately be ruled out as factors contributing to
changes in the Rluc8:fLuc ratio in STS-treated cells. It should be
noted that similar bioluminescent measurements were obtained
from live and lysed cells, nonetheless. Changes in the Rluc8:fLuc
ratio were also observed regardless of whether the coding
sequences for fLuc and RLuc8 were interchanged, relative to the
intervening internal ribosomal entry site, IRES (Figure S4).
Therefore, the presence of an IRES sequence can also be ruled
out as a factor contributing to the changes in the RLuc8:fLuc ratio
in STS-treated cells.
Protein levels, but not mRNA levels mimic
bioluminescent data
Quantitative RT-PCR and western blot analyses were per-
formed to determine whether changes in RNA or protein levels
Figure 1. Response of HeLa-fR cells to STS. HeLa-fR cells were treated with 10 mM STS for 24 hours. (a) Bioluminescent measurements of RLuc8
and fLuc were acquired at various times during the course of treatment. All measurements were normalized to values at 0 hours. The RLuc8:fLuc ratio
was subsequently calculated for each time point (right axis). (b) A representative bioluminescent image of RLuc8 and fLuc activity in STS-treated cells
is shown as well as the calculated ratiometric image, RLuc8:fLuc. (c) A TUNEL assay for DNA fragmentation was also performed at various times during
the course of STS treatment. Analogous bioluminescent and DNA fragmentation measurements were performed on RBS – HeLa cells that were
treated with a dosage range of STS for 6 hours. (d) Bioluminescent measurements of RLuc8 and fLuc activity in cells treated with various doses of STS.
The RLuc8:fLuc ratio is also shown (right axis). (e) Representative bioluminescent images of RLuc8 and fLuc activity in cells treated with various doses
of STS. The calculated ratiometric image of RLuc8:fLuc is also shown. (f) A TUNEL assay for DNA fragmentation was also performed on HeLa-fR cells
treated with various doses of STS.
doi:10.1371/journal.pone.0020073.g001
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compared with RLuc8 activity. Previous studies have shown that
oxidative stress can trigger the degradation of both mRNA [16]
and proteins [17]. If RNA was degraded, a drastic difference in the
relative level of fLuc and Rluc8 mRNA expression would be
expected after STS treatment, compared with PBS-treated
controls; however, this was not the case. Although slight reductions
in fLuc and RLuc8 RNA expression were observed in STS-treated
cells, the relative expression remained constant (Figure 2a). This
was not entirely surprising considering that fLuc and RLuc8 were
expressed as a single bicistronic RNA with an internal ribosomal
entry site (IRES). Since a single CMV promoter is used to drive
fLuc and RLuc expression, the differential response of fLuc and
RLuc8 activity to apoptosis also cannot be attributed to any
difference or changes in promoter activity.
In contrast to RNA expression, western blot analysis revealed
that fLuc protein levels decreased over the time course of STS
treatment, while Rluc8 protein levels remained relatively stable,
mirroring the bioluminescent measurements (Figure 2b). Addi-
tionally, several higher molecular weight bands were observed
after fLuc staining at the later time points, particularly 24 hours,
introducing the possibility of protein cross-linking and/or post-
translational modification.
Luciferin and Coelenterazine are not sensitive to
intracellular species or enzymes in stressed cells
Although western blotting revealed that there was a differential
loss in fLuc protein compared with RLuc8 in STS-treated cells
(Figure 2), because fLuc and RLuc8 also react with different
substrates (i.e. D-luciferin and coelenterazine, respectively) it
remained possible that various intracellular species or enzymes
could also exhibit a differential effect on the stability of these
substrates. To explore this possibility, wild-type HeLa cells were
treated either with STS or PBS for 24 hours. Subsequently, both
D-luciferin and coelenterazine (i.e. Dual-Glo) were added to the
cells, analogous to the studies above. This was followed by the
addition of purified fLuc and RLuc8 proteins. In this approach,
the bioluminescent proteins were not exposed to the harsh
intracellular environment during STS treatment and therefore
would, presumably, not be significantly affected by the intracel-
lular milieu. Bioluminescent measurements confirmed that at least
within the time frame of bioluminescence acquisition, intracellular
factors did not exhibit any appreciable effect on the fLuc or RLuc8
activity. Therefore, it can be concluded that the intracellular
species and enzymes present in apoptotic cells also did not have an
appreciable affect on the stability of D-luciferin and coelenterazine
(Figure S5).
H2O2 is prominently involved in the discrepancy between
fLuc and RLuc8 bioluminescence
To explicate the root cause responsible for the loss in fLuc
activity in STS-treated cells and the corresponding increase in the
Rluc8:fLuc ratio, systematic inhibition/scavenger studies were
performed to individually silence key pathways known to cause
protein degradation/modification. Figure S6 outlines some of the
key pathways that were investigated, which included proteasomal
and lysosomal pathways, apoptotic pathways, and oxidative stress.
The various inhibitors/scavengers that were tested and their
targets are listed in Table 1. It was expected that certain inhibitors
would rescue fLuc activity, resulting in a corresponding decrease
in the RLuc8:fLuc ratio in STS-treated HeLa-fR cells. Since the
proteasome is a prominent source of intracellular protein
degradation, it was naturally one of the first molecular entities
we investigated for the inhibition studies. Surprisingly, employ-
ment of the proteasome inhibitors MG-132, epoxomicin and
lactacystin did not rescue fLuc activity and actually led to an
increase in the RLuc8:fLuc ratio (Figure 3a), i.e. fLuc activity was
even further reduced relative to RLuc8. The efficacy of the
proteasome inhibitors was confirmed by performing analogous
studies with Proteasome-GLO (Figure S7a). These results provided
strong evidence that enhanced proteasomal degradation was not
responsible for the loss of fLuc activity in STS-treated cells.
Next, inhibitors for various proteases associated with apoptosis
and lysosomal degradation were evaluated, namely calpain
Inhibitor III (inhibits calpains), Pepstatin A (inhibits aspartyl
proteases), ammonium chloride (inhibits phagosome-lysosome
fusion), and z-vad-fmk (pan caspase inhibitor). As shown in
Figure 3b, none of these inhibitors significantly affected the
Rluc8:fLuc ratio of STS-treated cells. The efficacy of the various
protease inhibitors was confirmed by appropriate commercial
assays (Figure S7b). While the increase in the Rluc8:fLuc ratio
observed upon use of the Calpain Inhibitor III on untreated
(–STS) cells requires further exploration, one possible explanation
may involve the decrease of intracellular antioxidant glutathione
(GSH) levels and the associated increase in oxidative stress that has
been shown to occur with the addition of this inhibitor[18].
Once the proteasome and various proteases were shown to have
insignificant effectson the mechanism responsiblefortheincrease in
the Rluc8:fLuc ratio in STS-treated cells, focus was shifted to three
oxygen byproducts associated with oxidative stress, i.e. superoxide
Figure 2. Assessment of mRNA and protein levels in STS-treated HeLa-fR cells. (a) Normalized RLuc8 and fLuc mRNA levels in HeLa-fR cells
treated with PBS (control, C) or 10 mM STS (STS) for 24 hours. mRNA levels were determined by qRT-PCR. (b) Western blot of HeLa-fR cells treated with
PBS (-) or 10 mM STS (+) over a time course of 24 hours. b-actin is shown as a loading control.
doi:10.1371/journal.pone.0020073.g002
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N-), hydroxyl radical (
NOH) and hydrogen peroxide (H2O2).
Three O2
N- scavengers were tested - Tiron, TEMPOL (both cell-
permeable O2
N- scavengers) and MnTMPyP (a cell-permeable
superoxide dismutase (SOD) mimetic) - for their ability to reduce
the Rluc8:fLuc ratio by rescuing fLuc activity. As shown in
Figure 3c, none of the superoxide scavengers significantly reduced
the Rluc8:fLuc ratio. The efficacy of the O2
N- scavengers was
confirmed by performing a dihydroethidium assay (Figure S7c).
Next, three
NOH scavengers/inhibitors, namely mannitol
(specific
NOH scavenger), deferoxamine (DFO, iron chelator) and
tetraethylenepentamine (TEPA, copper chelator) were examined.
The two metal chelators, alone and in combination, were used to
effectively reduce the amounts of metals available for the Fenton
reaction (Fe





NOH scavengers/inhibitors provided protection for fLuc
activity. Accordingly, these agents did not reduce the Rluc8:fLuc
ratio in STS-treated cells (Figure 3d). It may be argued that the
slight increase in Rluc8:fLuc ratio that was observed following the
addition of TEPA to the HeLa-fR cells could be a result of excess
H2O2 buildup from the prevention of the Fenton reaction,
however further studies are warranted especially since the
combination of DFO + TEPA did not yield an additive effect.
The effective reduction of intracellular
NOH following the addition
of each scavenger/inhibitor was confirmed by a decrease in
hydroxyphenyl fluorescein fluorescence (Figure S7d).
The final group of inhibitors/scavengers that were examined
was associated with reducing intracellular H2O2 levels, i.e. catalase
(scavenger), allopurinol (xanthine oxidase (XO) inhibitor), and
acetylsalicylic acid (aspirin, cyclooxygenase (COX) inhibitor).
Catalase converts H2O2 to water, allopurinol inhibits XO, an
enzyme that catalyzes the oxidation of hypoxanthine and
xanthine, creating H2O2 as a byproduct, and aspirin inhibits
COX enzymes, which possess peroxidase activity. The addition of
all three of these reagents resulted in significant reduction
(p,0.01) in the Rluc8:fLuc ratio, as seen in Figure 3e. It should
be noted that catalase cannot cross cell membranes, but our results
are consistent with previous studies reporting that extracellularly
added catalase is effective at removing intracellular H2O2, likely
by creating an extracellular sink [19,20]. A reduction in
intracellular H2O2 following the addition of each inhibitor/
scavenger was confirmed by a decrease in CM-H2DCFDA
fluorescence (Figure S7e).
The potential involvement of H2O2 in the loss in fLuc activity in
STS-treated cells is consistent with earlier findings. For example,
the higher molecular weight fLuc bands that were observed in
Figure 2 could be the result of peroxidase-catalyzed H2O2–
dependent cross-linking. Further, the increase in the RLuc8:fLuc
ratio that was observed upon pre-treating stressed cells with
proteasome inhibitors could also be explained by the H2O2-
medited reduction in fLuc activity since proteasome inhibition has
previously been associated with an increase intracellular ROS
levels [21,22,23,24]. Perhaps, it was somewhat surprising that the
superoxide scavengers TIron, TEMPOL and MnTMPyP resulted
in little to no increase in the RLuc8:fLuc ratio considering that
superoxide is a precurser of H2O2; however, measurements of
H2O2 via CM-H2DCFDA fluorescence also indicated that Tiron,
TEMPOL, and MnTMPyP had no statistically significant effect
on H2O2 levels in STS-treated cells (Figure S8).
Table 1. Reagents, manufacturers and working concentrations used in this study.
Reagent Manufacturer Working Concentration
Stress
Inducers
Staurosporine (STS) Sigma 0–50 mM
Hydrogen Peroxide (H2O2) Fisher 0–10 mM
Hypoxanthine (HX) Sigma 50 mM
Xanthine Oxidase (XO) Sigma 25 mU/mL
Proteasome Inhibitors MG-132 Fisher 20 mM
Epoxomicin Enzo Life Sciences 10 mM
Lactacystin Sigma 10 mM
Protease
Inhibitors
Calpain Inhibitor III Calbiochem 100 mM
Pepstatin A Enzo Life Sciences 100 mM
Ammonium Chloride Alfa Aesar 1 mM




Tiron Sigma 10 mM
TEMPOL Sigma 10 mM
MnTMPyp Enzo Life Sciences 100 mM
NOH scavengers Mannitol Sigma 100 mM
DFO Calbiochem 50 mM
TEPA Sigma 50 mM
H2O2-
related Inhibitors
Catalase Sigma 40 U/mL
Allopurinol MP Biomedicals 100 mM
Acetylsylic Acid (Aspirin) Fisher 1 mM
doi:10.1371/journal.pone.0020073.t001
Firefly Luciferase Is Sensitive to ROS
PLoS ONE | www.plosone.org 4 May 2011 | Volume 6 | Issue 5 | e20073Catalase, allopurinol and aspirin rescue fLuc in a dose-
dependent manner and rescue fLuc protein levels in STS
treated cells
To validate the protective effect of H2O2 inhibitors/scavengers
on fLuc activity, HeLa-fR cells were pretreated with increasing
doses of catalase (Figure 4a), allopurinol (Figure 4b) or aspirin
(Figure 4c) for 1 hour prior to the addition of 10 mM STS. After a
24 hr incubation period with the various H2O2 inhibitors/
scavengers and STS, the bioluminescent ratio was measured. It
was found that each inhibitor/scavenger effectively rescued fLuc
activity, thus reducing the Rluc8:fLuc ratio, in a dose-dependent
manner. A Western blot was also performed to directly determine
the effect of the various H2O2 inhbitors/scavengers on biolumi-
nescent protein levels. Consistent with the observed recovery in
fLuc activity, STS-treated HeLa-fR cells that were pretreated with
catalase, allopurinol, or aspirin exhibited higher levels of fLuc
protein (Figure 4d, column 3–5) compared to cells treated with
STS in the absence of inhibitor (i.e. PBS, column 2).
Allopurinol can rescue fLuc activity, independent of cell
death
Although pretreating HeLa-fR cells with allopurinol, prior to
the addition of STS, helped decrease the Rluc8:fLuc ratio by
stabilizing fLuc activity (Figure 5a) and reducing intracellular
H2O2 levels as determined by CM-H2DCFDA (Figure 5b),
TUNEL assays revealed that allopurinol did not provide
protection against cell death (Figure 5c). These findings demon-
strate that the processes associated with fLuc inactivation are
separate and distinct from cell death, further supporting the notion
that the various proteases that are activated/upregulated in
apoptotic cells are not responsible for fLuc inactivation. Moreover,
considering that allopurinol specifically inhibits xanthine oxidase,
a significant source of hydrogen peroxide (and superoxide and
hydroxyl radicals to a lesser extent), these findings provide strong
evidence that ROS are primarily responsible for fLuc inactivation
in apoptotic cells. It is also interesting to note that since significant
reductions in the intracellular level of H2O2 did not prevent cell
death, these results also indicate that H2O2 is not essential for the
progression of programmed cell death in STS-treated HeLa cells,
but rather is a downstream byproduct.
fLuc activity in cells is highly responsive to H2O2
Having shown that various inhibitors/scavengers of H2O2
exhibited a stabilizing affect on fLuc activity in apoptotic cells,
additional studies were performed that dealt with H2O2 more
directly. First, we investigated the response of HeLa-fR cells to the
hypoxanthine (HX)-XO reaction, which allowed for the continual
Figure 3. Inhibition studies to determine mechanism responsible for activation of the RBS. HeLa-fR cells were pretreated with (a)
proteasome inhibitors, (b) protease inhibitors, (c) O2
N- scavengers, (d)
NOH scavengers, or (e) H2O2-related scavengers for 1 hour, followed by PBS
(white bars) or 10 mM STS for 24 hours (gray bars). The RLuc8:fLuc ratio was calculated and reported. Statistical significance between control (+STS)
and individual inhibitors/scavengors (+STS) is indicated with a ** (p,0.01).
doi:10.1371/journal.pone.0020073.g003
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that the bioluminescent ratio increased dramatically, reaching
levels that were significantly higher than what was observed
previously with STS treatment (Figure 6a). Additionally, it was
found that the HX-XO reaction did not cause cell death, as
indicated by a TUNEL assay (Figure 6b). These results provide
additional evidence that the observed loss in fLuc activity is
specifically associated with elevated levels of ROS as opposed to
other mechanisms that are a consequence of cell death.
Second, to specifically reduce H2O2 in apoptotic cells, HeLa-fR
cells were infected with an adenoviral vector coding for catalase,
prior to STS treatment. Overexpression of catalase led to a
dramatic improvement in the stability of fLuc activity in STS-
treated HeLa-fR cells and a corresponding decrease in the
Rluc8:fLuc ratio, compared with control cells (i.e. cells treated with
STS and empty adenovirus) (Figure 6c). A reduction in intracellular
H2O2 in cells pretreated with adenovirus-catalase was confirmed by
a decrease in CM-H2DCFDA fluorescence (Figure 6d).
Figure 4. Dose response of HeLa-fR cells to H2O2-related scavengers/inhibitors. HeLa-fR cells were pretreated with a dosage range of (a)
catalase, (b) allopurinol, or (c) aspirin for 1 hour prior to incubating with 10 mM STS (solid lines, +STS) or PBS (dotted lines, -STS) for 24 hours. The
RLuc8:fLuc ratio was calculated and reported. (d) HeLa-fR cells were pretreated for 1 hour with PBS, 50 U/mL catalase, 100 mM allopurinol or 1 mM
aspirin (columns 2–5) prior to the administration 10 mM STS for 24 hours. A western blot was subsequently performed with anti-fLuc and anti-RLuc
antibodies. b-actin is shown as a loading control.
doi:10.1371/journal.pone.0020073.g004
Figure 5. Effect of allopurinol pretreament on STS-treated HeLa cells. HeLa-fR cells were pretreated with either 100 mM allopurinol or PBS
for 1 hour prior to the administration of 10 mM STS or PBS. After 24 hours, (a) the RLuc8:fLuc ratio, (b) intracellular H2O2 levels as measured by CM-
H2DCFDA, and (c) DNA fragmentation levels, as measured using a TUNEL assay, were recorded for each sample. Statistical significance: *(p,0.05),
**(p,0.01).
doi:10.1371/journal.pone.0020073.g005
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inactivation
It is widely acknowledged that oxidatively-modified proteins can
be targeted to the proteasome for degradation [25]. To investigate
whether the proteasome was ultimately responsible for the
degradation of fLuc following ROS-mediated inactivation in
STS-treated cells, a western blot was performed on cells that were
pretreated with the proteasome inhibitors MG-132, epoxomicin or
lactacystin prior to the administration of STS. As shown in
Figure 7, none of the proteasome inhibitors examined were
capable of preventing fLuc degradation. These findings provide
strong evidence that fLuc was not degraded by the proteasome
secondary to inactivation. This leaves open the possibility that
oxidatively-modified proteins are specifically degraded via other
proteases; however, this seems unlikely considering the degrada-
tion of oxidatively-modified proteins is generally a well accepted
physiological function of the proteasomal system, with proteolysis
by the 20S proteasome being the major pathway.[17,25,26]
Taking this into consideration, we suspect that ROS may be
directly responsible for the degradation of fLuc. It has been well
documented that peptide bond cleavage can occur as a result of
ROS attack.[27,28] The formation of protein aggregates and/or
cross-linking of fLuc may also contribute to the apparent loss in the
wild-type fLuc band on western blots of STS-treated cells,[25] but
it is hypothesized that protein cleavage is the predominant
mechanism considering that cross-linking was only observed on
western blots after long exposures to STS (Figure 2).
Discussion
In this study, we found that fLuc activity was rapidly lost in
apoptotic cells, while RLuc8 exhibited significantly prolonged
functionality under the same conditions. Inhibition assays that
targeted intracellular protein degradation/modification pathways
that are often involved in apoptosis suggested that ROS, primarily
H2O2, were responsible for the rapid loss in fLuc activity.
Consistent with these findings, allopurinol, an inhibitor of
xanthine oxidase-a primary source of intracellular ROS, aspirin,
a COX inhibitor, and catalase, an H2O2 scavenger, all exhibited a
dose-dependent protective effect on fLuc activity in apoptotic cells.
Notably, none of these H2O2 scavengers/inhibitors interfered with
cell death, providing further evidence that the proteases and
degradation pathways triggered with STS treatment and necessary
for cell death were not responsible for the loss in fLuc activity,
since these mechanisms will have remained activated after
antioxidant treatment.
To directly demonstrate that oxidative stress could lead to the
preferential loss of fLuc activity, compared with RLuc8, HX-XO
was used to generate H2O2 in the media of HeLa-fR cells. As
expected, the bioluminescent ratio, RLuc8:fLuc, increased dra-
Figure 6. Response of HeLa-fR cells to a hypoxanthine (HX)-xanthine oxidase (XO) reaction and the affect of adenovirus-catalase on
STS-treated cells. (a) HeLa-fR cells were subjected to the HX-XO reaction (50 mM HX, 25 mU/mL XO) or PBS (Control) for 24 hours. The RLuc8:fLuc
ratio was calculated and reported. (b) A TUNEL assay was used to determine the percent DNA fragmentation, following exposure to HX-XO. (c) HeLa-
fR cells were treated with adenovirus-catalase (Adv-Cat) or empty adenovirus (Adv-E) for 24 hours, washed, and incubated in serum-containing media
for another 24 hours. Then, 10 mM STS or PBS was added to the cells. After 24 hours the RLuc8:fLuc ratio was calculated and reported. (d) HeLa-fR
cells were subjected to the same conditions as in (c) but assayed for H2O2 levels using CM-H2DCFDA.
doi:10.1371/journal.pone.0020073.g006
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levels that were below the threshold needed to cause cell death.
Therefore, a state of oxidative stress was created that was
independent of any processes associated with cell death.
Currently, it remains unclear whether amino acid modifications
or peptide cleavage, as a result of ROS attack, is ultimately
responsible for the loss in fLuc activity. Certainly, both
mechanisms could play a role. Protease-mediated degradation of
oxidatively modified proteins can also not be ruled out completely;
however, considering that selective degradation of oxidatively-
modified proteins is the physiological function of the proteasomal
system[17,25,26] and inhibition of this system did not prevent the
loss of the fLuc band on western blots, it seems more likely that
any degradation observed was the direct result of ROS attack.
Common targets for H2O2-mediated modifications include but
are not limited to methionine (M), cysteine (C), histidine (H),
tyrosine (Y) and phenylalanine (F), (see [17], for review), often
creating hydroxyl- or carbonyl-derivatives. Glutamyl (E), aspartyl
(D), and prolyl (P) side chains are common sites for peptide bond
cleavage as a result of oxidative stress. Since the proposed active
site (i.e. luciferin binding site) for fLuc is 244H-H-G-F247 [29],
there are a number of potential amino acid substrates for oxidative
modification. However, it should be noted that the proposed active
site for rLuc, D120, E144, and H285, also contains multiple
targets for ROS [14]. Therefore, it not clear whether the
differential sensitivity of fLuc and RLuc8 to H2O2 can be
attributed to modifications within these proposed active sites
alone. Further, there is still some uncertainty regarding the exact
amino acids of fLuc that are involved in substrate binding and
enzyme catalysis [30,31]. Other amino acids that have been
identified as being important for bioluminescence include S198,
K206, Y340, T343, E344, E389 and Y401[32]. It is possible that
the H2O2-mediated modification of various amino acids and/or
combinations of amino acids could all lead to the inactivation of
fLuc. Certainly, peptide cleavage at any location within the amino
acid sequence of fLuc could lead to inactivation of fLuc, as well. In
fact, it has been shown that even just the removal of a few amino
acids from the N- or C-terminus from fLuc can cause a dramatic
loss in fLuc activity.[33,34] Future studies (e.g. mass spectroscopy,
mutagenesis, and functionality assays) will be aimed at analyzing
various location(s) and types of amino acid modifications and
cleavage products to determine which could lead to a diminution
of fLuc activity.
Despite the uncertainty regarding the specific amino acid
modifications or cleavage sites responsible for the inactivation of
fLuc, we have shown here that the bioluminescent ratio
RLuc8:fLuc can still be used to relay important information
regarding intracellular levels of ROS, in particular hydrogen
peroxide [35,36]. For example, we showed that the increase in the
level of intracellular H2O2 in various cases of cell death was
consistently reflected by an increase in the RLuc8:fLuc ratio. Of
course, these studies do not rule out the possibility that other
factors could also have a differential effect on fLuc and RLuc;
however, the contribution of ROS to the loss of fLuc activity can
be established by performing control studies with H2O2-specific
scavengers/inhibitors.
Arguably, measurements of RLuc8:fLuc ratiocould thus beused to
assist with the identification and evaluation of any cancer therapeutics
that induce elevated levels of ROS. This is likely to include
compounds that induce cell death through caspase-dependent and
caspase-independent pathways [10,22,36,37,38,39,40,41]. Applica-
tions related to caspase-independent cell death are of particular
interest considering that anticancer drug resistance and tumorigenesis
havebeenlinkedtotheabilityofcertaincancertypestoevadecaspase
activation [42,43]. Currently, there is a dearth of tools available for
the study of caspase-independent cell death. Therefore, having a
bioluminescent read-out that can potentially be translated from
benchtop assays to in vivo disease models is particularly beneficial.
With an increasing number of pathologies being linked to oxidative
stress, including atherosclerosis, cancer, cystic fibrosis, type-2
diabetes, and Alzheimer’s disease, the ability to detect oxidative
stress is also expected to allow for advances in anti- and pro-oxidant
research across a wide range of disciplines.
Materials and Methods
Plasmid Vector Construction
The internal ribosome entry site (IRES) from the pIRES2-
DsRed Express Vector (Clontech, Mountain View, CA, USA) was
cloned into the pIRES vector (Clontech) using restriction enzymes
NheI and KpnI (New England Biolabs, Ipswich, MA, USA),
creating the pIRES12 vector. The phRL-CMV vector (Promega,
Madison, WI, USA) encoding Renilla Luciferase was modified to
contain eight amino acid mutations within the rLuc sequence
(A55T, C124A, S130A, K136R, A143M, M185V, M253L, and
S287L) using the QuikChange Multi Site Directed Mutagenesis
Kit (Stratagene, La Jolla, CA, USA) according to the manufac-
turer’s instructions, ultimately creating RLuc8. The DNA
sequence encoding Firefly Luciferase (fLuc) from the pGL3-Basic
vector (Promega) was PCR amplified and inserted into
pCDNA3.1+ (Invitrogen, Carlsbad, CA, USA) between the
BamHI and EcoRI restriction sites. The fLuc sequence was
subsequently cloned into pIRES12 using the NheI and XbaI
restriction sites of fLuc-pCDNA3.1+ and the XbaI site of
Figure 7. Assessment of fLuc and RLuc8 protein levels in HeLa-fR cells pre-treated with proteasome inhibitors prior to the
administration of STS. HeLa-fR cells were pretreated for 1 hour with PBS, 20 mM MG-132, 10 mM Epoxomicin or 10 mM Lactacystin prior to the
administration of PBS (-) or 10 mM STS (+) for 24 hours. A western blot was subsequently performed with anti-fLuc and anti-RLuc antibodies. b-actin is
shown as a loading control.
doi:10.1371/journal.pone.0020073.g007
Firefly Luciferase Is Sensitive to ROS
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e20073pIRES12. RLuc8 was cloned into the pIRES12-fLuc vector at the
NheI and BglII restriction sites. The resulting Rluc8-IRES-fLuc
sequence was cloned into the pLENTI6/V-5 TOPO vector
(Invitrogen) per the manufacturer’s instructions to create the fLuc-
RLuc8 (fR) vector.
Cell Culture
Human cervical carcinoma (HeLa) and human breast adeno-
carcinoma (MCF7) cells (ATCC, Manassas, VA) were grown in
Eagle’s Minimum essential medium (Mediatech, Manassas, VA)
supplemented with 10% fetal bovine serum (FBS, HyClone,
Logan, UT), 1.5 g/L sodium bicarbonate, 100 U/mL penicillin
and 100 mg/mL streptomycin (Invitrogen). Human embryonic
kidney (293T/17) cells (ATCC) were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM, Mediatech) supplemented
with 10% FBS (Hyclone), 1.5 g/L sodium bicarbonate, 100 U/
mL penicillin and 100 mg/mL streptomycin (Invitrogen). The
genetically modified human embryonic kidney cells (293FT,
Invitrogen) for generating lentiviral particles were cultured in
Dulbecco’s Modified Eagle’s Medium (DMEM, Mediatech)
supplemented with 10% fetal bovine serum (FBS, HyClone,
Logan, UT), 1.5 g/L sodium bicarbonate, 1 mM sodium
pyruvate, 0.1 mM MEM non-essential amino acids (NEAA),
6 mM L-glutamine, 100 U/mL penicillin and 100 mg/mL
streptomycin (Invitrogen). Cells that were genetically engineered
to stably express the fR vector (described below) also had
Blasticidin (Invitrogen) added at a final concentration of 4 mg/
mL. All cells were cultivated in a 37uC humidified incubator with
5% CO2.
Lentiviral Particle Production and Stable Cell Line
Creation
Lentiviral particles containing the fR vector were produced
using the Virapower Lentiviral Directional TOPO Expression Kit
(Invitrogen) according to the manufacturer’s insctructions. Briefly,
293FT cells were transfected with viral packaging plasmids and the
fR lentiviral vector using Lipofectamine 2000 (Invitrogen). Viral
supernatant was harvested 48 hours after transfection, concen-
trated using Peg-it Virus Concentration solution (System Biosci-
ences, Mountain View, CA, USA) and the titer was assessed.
Concentrated viral particles were added to HeLa cells, which were
subsequently selected for stable genomic integration using
Blasticidin (Invitrogen), resulting in HeLa-fR cells.
Inhibition Assays
To induce cellular stress, HeLa cells were treated with
Staurosporine (STS), hydrogen peroxide, or hypoxanthine and
xanthine oxidase for 0 to 24 hours at concentrations indicated in
Table 1. Stressed and unstressed cells were also incubated with
inhibitors that target various intracellular protein degradation/
modification pathways. The specific compounds/proteins that
were utilized as inhibitors and the respective final working
concentrations are also listed in Table 1. Inhibitors were added
to cells 1-hr prior to adding inducers of cellular stress and left in
the media for the duration of the treatment. Analogous controls
were conducted in the absence of stress inducers.
Apoptosis Induction
To induce apoptosis, cells were treated with staurosporine (STS)
(Sigma, St. Louis, MO) in complete medium at indicated
concentrations and time points. In studies where allopurinol (Allo,
MP Biomedicals) is used as an inhibitor, it was added at a final
concentration of 100 mM to cells in complete medium for 1 hour
prior to the addition of the death-inducing drugs and remained in
the medium throughout the study.
Cellular Bioluminescence Assays
Unless otherwise noted, bioluminescence assays were performed
24 hours after plating 10,000 HeLa-fR cells/well in a white-walled
96 well tissue culture plate (BD Biosciences, Franklin Lakes, NJ,
USA). The Dual-Glo Luciferase Assay System (Promega) was
utilized according to the manufacturer’s instructions to obtain
both fLuc and Rluc8 bioluminescence measurements from an
Infinite 200 plate reader (Tecan, Mannedorf, Switzerland). In the
case of using MnTMPyP as an inhibitor, the cell media was
removed, cells were gently washed and the media was replaced
before using the Dual-Glo Luciferase Assay System as it was
found that the compound interfered with the bioluminescence
measurements.
Adenovirus Infection
5000 Hela-fR cells/well were plated in a white-walled 96-well
tissue culture plate (BD Biosciences). The following day, catalase
adenovirus (Adv-Cat, Vector Biolabs, Philadelphia, PA) was added
to the cells at an MOI of 200. Cells were incubated at 37uC for
one hour, with gentle rocking occurring every 15 minutes. Virus-
containing media was then replaced with normal growth media.
Cell death and bioluminescence assays were performed beginning
on the following day, using methods previously outlined.
Cell Death Assays
Caspase Activity. PCD was induced (as described above)
24 hours after plating 10,000 cells/well in white-walled 96 well tissue
culture plates (BD Biosciences). After indicated treatment times, the
Caspase 3/7-Glo Assay (Promega) was performed according to the
manufacturer’s protocol and bioluminescence measurements were
obtained from and Infinite 200 plate reader (Tecan). All values were
normalized to controls (i.e. pre-treatment values).
DNA Fragmentation
PCD was induced (as described above) 24 hours after plating
300,000 cells/well in 6 well tissue culture plates (BD Biosciences).
After indicated treatment times, TUNEL assays for DNA
fragmentation were performed using the TUNEL/ApoBRDU
assay kit (Invitrogen) according to the manufacturer’s protocol.
Percent DNA fragmentation was determined using flow cytometry
on a Guava EasyCyte flow cytometer (Guava Technologies,
Hayward, CA). Analysis of flow cytometry data was performed
using FlowJo software (Treestar, Ashland, OR).
Quantitative Real Time PCR
Cytoplasmic RNA from HeLa-fR cells cultured under indicated
conditions was isolated using the High Pure RNA Isolation Kit
(Roche, Mannheim, Germany) and subsequently reverse-tran-
scribed to single-stranded cDNA using a High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Foster City, CA,
USA) according to each manufacturer’s protocol. Quantitative
RT-PCR was performed on an ABI PRISM 7300 Sequence
detection system using FAM-labeled Taqman primer sets for
Rluc8, fLuc and b-actin (as a control) and the Taqman universal
PCR Master Mix (Applied Biosytems) according to the manufac-
turer’s protocol.
Western Blotting
Following indicated culture conditions, HeLa-fR cells were
washed 3 times with 1x PBS (pH 7.4). Proteins were extracted
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Triton X-100, 0.25% Na-deoxycholate, 150 mM NaCl, 1 mM
EDTA and a Complete Mini Protease Inhibitor Cocktail Tablet
(Roche)) at 4uC for 30 minutes with constant agitation. Total
protein concentrations were measured using a BCA assay (Pierce,
Rockford, IL, USA). 30 mg of total protein from each sample were
heated to 95uC in Laemmli Sample buffer containing 2% (v/v) 2-
mercaptoethanol (Bio-Rad, Hercules, CA, USA). After a 5 minute
cooling period, the samples were quickly centrifuged and the
supernatants were immediately run on a 4–15% Tris-HCl gel (Bio-
Rad). Proteins separated by electrophoresis were transferred to
nitrocellulose membranes in 1X Transfer Buffer (Bio-Rad) at 15 V
for 30 minutes. Membranes were blocked in Blocking Buffer for
Fluorescent Western Blotting (Rockland Immunochemicals, Gil-
bertsville, PA, USA) for 60 minutes. The membranes were
incubated with anti-fLuc (Sigma), anti-rLuc (Millipore, Billerica,
MA) or anti-b-actin (Abcam, Cambridge, MA) primary antibodies
in blocking buffer overnight. After washing 3 times with TBS-T,
the membranes were incubated with either Anti-Mouse IgG
Antibody IRDye800 conjugated (fLuc, rLuc) or Anti-Rabbit IgG
Antibody IRDye800 conjugated (b-actin) at a 1:10,000 dilution
(Rockland Immunochemicals). The fluorescent signal from the
membranes was imaged using the Odyssey Infrared Imaging
System (Li-Cor Biosciences, Lincoln, NE, USA).
Cellular Bioluminescence Imaging
HeLa-fR cells were plated at a density of 10,000 cells/well in a
black-walled 96 well tissue culture plate (BD Biosciences). The
Dual-Glo Luciferase Assay System (Promega) was utilized
according to the manufacturer’s instructions in order to obtain
bioluminescent images in an Omega 16 vs imaging system
(UltraLum, Claremont, CA, USA). It should be noted that the
exact position of the 96 well plate was kept constant throughout
the imaging session in order for accurate ratiometric images to be
calculated.
Microplate Image Analysis
All image analyses were performed using ImageJ (NIH,
Bethesda, MD, USA). Image background was determined by
measuring 3 regions of interest (ROIs) surrounding the biolumi-
nescent ROI. After background subtraction, the RLuc8 image was
divided by the fLuc image using the ‘Math’ command under the
‘Process’ menu tab.
Assessing Sensitivity of Bioluminescent Substrates to
Intracellular Species
HeLa cells were plated at a density of 10,000 cells/well in a
white-walled 96-well plate (BD Biosciences). 24 hours later, cells
were treated with PBS (pH 7.4) or 10 mM STS. Following a
24 hour incubation, Dual-Glo (Promega) substrates were applied
to the cells along with 650 nM purified fLuc and RLuc8 proteins.
Bioluminescence measurements were obtained from an Infinite
200 plate reader (Tecan).
Switching of fLuc and RLuc8 relative to the IRES
sequence
The RLuc8 sequence was PCR amplified and cloned into
pCDNA3.1+ between the BamHI and EcoRI restriction sites,
creating RLuc8-pCDNA2.1+. RLuc8 was subsequently cloned
into pIRES12 using the NheI and XbaI restriction sites of RLuc8-
pCDNA3.1+ and the XbaI site of pIRES12, creating pIRES12-
RLuc8. The fLuc sequence was PCR amplified and inserted into
pCDNA3.1+ between the BamHI and EcoRI restriction sites. The
fLuc sequence was subsequently cloned into the pIRES12-RLuc8
vector at the NheI and BglII restriction sites. The resulting fluc-
pIRES-RLuc8 sequence was cloned into the pLENTI6/V-5
TOPO vector per the manufacturer’s instructions to create the
final vector necessary for the reverse RBS.
Proteasome Inhibition Control Assay
HeLa-fR cells were plated at a density of 10,000 cells/well in a
white-walled 96-well plate (BD Biosciences). 24 hours later, cells
were treated with PBS (pH 7.4), 20 mM MG-132, 10 mM
epoxomicin or 10 mM lactacystin for 1 hour. HeLa-fR cells were
then treated with PBS (pH 7.4) or 10 mM Staurosporine (STS) in
addition to the inhibitors for 24 hours. Proteasome activity
measurements were obtained using the Proteasome-Glo 3-
Substrate Cell-Based Assay system (Promega) according to the
manufacturer’s instructions.
Protease Inhibition Control Assays: Calpain Inhibitor III
HeLa-fR cells were plated at a density of 10,000 cells/well in a
white-walled 96-well plate (BD Biosciences). 24 hours later, cells
were treated with either PBS (pH 7.4) or 100 mM Calpain
Inhibitor III for 1 hour. PBS (pH 7.4) or 10 mM STS was
subsequently added to the cells, and both compounds remained on
the cells for 24 hours. Calpain activity measurements were
obtained using the Calpain-Glo Protease Assay (Promega)
according to the manufacturer’s instructions.
Pepstatin A
HeLa-fR cells were plated at a density of 10,000 cells/well in a
black-walled 96-well plate (BD Biosciences). 24 hours later, cells
were treated with either PBS (pH 7.4) or 100 mM pepstatin A for
1 hour, with either PBS (pH 7.4) or 10 mM STS added for another
24 hours. Cathepsin activity was assessed using the CV-Cathepsin
B Detection Kit (Enzo Life Sciences) according to the manufac-
turer’s instructions with one exception; after the final wash step,
the plate was read on an Infinite 200 plate reader (Tecan) for
fluorescence (550ex/610em), as opposed to microscopy.
Ammonium Chloride
In lieu of a control assay for ammonium chloride effectively
inhibiting lysosome-phagosome fusion, we direct the reader to a
seminal paper regarding this phenomena in HeLa cells [1].
z-vad-fmk
HeLa-fR cells were plated at a density of 10,000 cells/well in a
white-walled 96-well plate (BD Biosciences). 24 hours later, cells
were treated with either PBS (pH 7.4) or 1 mM z-vad-fmk for
1 hour. PBS (pH 7.4) or 10 mM STS was subsequently added to
the cells, and both compounds remained on the cells for 24 hours.
Caspase activity measurements were obtained using the Caspase-
Glo 3/7 Assay (Promega) according to the manufacturer’s
instructions.
Superoxide (O2
N-) Scavenger Control Assay
HeLa-fR cells were plated at a density of 120,000 cells per well
of a 12 well tissue culture plate (BD Biosciences). 24 hours later,
cells were treated with PBS (pH 7.4), 10 mM TEMPOL, 10 mM
Tiron or 100 mM MnTMPyP for 1 hour. PBS (pH 7.4) or 10 mM
STS was subsequently added to the cells, and both compounds
remained on the cells for 24 hours. Intracellular O2
N- levels were
then determined by incubating the cells in 5 mM dihydroethidium
(DHE, Invitrogen) for 30 minutes at 37uC and subjecting them to
flow cytometry using a Guava EasyCyte (Guava Technologies,
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accomplished using FlowJo software (TreeStar, Ashland, OR,
USA).
Hydroxyl Radical (
NOH) Scavenger/Inhibitor Control Assay
HeLa-fR cells were plated at a density of 120,000 cells per well
of a 12 well tissue culture plate (BD Biosciences). 24 hours later,
the cells were incubated with 10 mM hydroxyphenylfluorescein
(HPF, Sigma) for 30 minutes at 37uC. Cells were then treated with
PBS (pH 7.4), 100 mM Mannitol, 50 mM deferoxamine (DFO),
50 mM tetraethylenepentamine (TEPA) or 50 mM DFO plus
50 mM TEPA for 1 hour. PBS (pH 7.4) or 10 mM STS was
subsequently added to the cells, and all compounds remained on
the cells for 24 hours. Intracellular
NOH levels were determined by
subjecting the cells to flow cytometry using a Guava EasyCyte
(Guava Technologies). Analysis of flow cytometry data was
accomplished using FlowJo software (TreeStar).
Hydrogen Peroxide (H2O2)-related Inhibitor Control
Assays: Catalase and Allopurinol
HeLa-fR cells were plated at a density of 120,000 cells per well of
a 12 well tissue culture plate (BD Biosciences). 24 hours later, the
cells were incubated with 10 mM CM-H2DCFDA (Invitrogen) for
30 minutes at 37uC. Cells were then treated with PBS (pH 7.4),
50 U/mL catalase or 100 mM allopurinol for one hour. PBS
(pH 7.4) or 10 mM STS was subsequently added to the cells, and all
compounds remained on the cells for 24 hours. Intracellular H2O2
levels were determined by subjecting the cells to flow cytometry
using a Guava EasyCyte (Guava Technologies). Analysis of flow
cytometry data was accomplished using FlowJo software (Treestar).
Aspirin
HeLa-fR cells were plated at a density of 1.2610
6 cells in
100 mM tissue culture dishes (BD Biosciences). 24 hours later, the
cells were treated with PBS (pH 7.4) or 1 mM aspirin for one hour,
followed by PBS (pH 7.4) or 10 mM STS for 24 hours. Cycloox-
ygenase (COX) activity was determined by using the Cox Activity
Assay Kit (Cayman Chemical Company, Ann Arbor, MI, USA).
H2O2 Detection in Cells treated with Superoxide
Scavengers
HeLa-fR cells were plated at a density of 120,000 cells per well
of a 12 well tissue culture plate (BD Biosciences). 24 hours later,
the cells were incubated with 10 mM CM-H2DCFDA (Invitrogen)
for 30 minutes at 37uC. Cells were then treated with PBS (pH 7.4),
10 mM TEMPOL, 10 mM Tiron or 100 mM MnTMPyP for
1 hour. PBS (pH 7.4) or 10 mM STS was subsequently added to
the cells, and both compounds remained on the cells for 24 hours.
Intracellular H2O2 levels were determined by subjecting the cells
to flow cytometry using a Guava EasyCyte (Guava Technologies).
Analysis of flow cytometry data was accomplished using FlowJo
software (Treestar).
Supporting Information
Figure S1 Analysis of RLuc8:fLuc ratio as a function of
time and cell number. (a) For a fixed cell seeding density, the
RLuc8 and fLuc bioluminescent signal that was elicited by HeLa-
fR cells (PBS-treated) was detected over the course of 24 hrs (left
axis) and the RLuc8:fLuc ratio was calculated at each time point
(right axis). (b) HeLa-fR cells were plated at various cell densities
and the RLuc8:fLuc ratio was measured.
(TIF)
Figure S2 Caspase 3/7 activity in STS-treated HeLa-fR
cells. (a) HeLa-fR cells were treated with 10 mM STS or PBS
(untreated) for up to 24 hours. A Caspase-Glo 3/7 assay
(Promega) was performed at various times during the course of
treatment. All measurements were normalized to values at
0 hours. (b) HeLa-fR cells were treated with 0–50 mM STS of
PBS (untreated) for 6 hours followed by a Caspase-Glo 3/7 assay
(Promega). All measurements were normalized to values at 0 mM
STS.
(TIF)
Figure S3 Response of MCF7 and 293T/17 cells to
increasing doses of STS. (a–c) MCF7-fR and (d–f) 293T/17-
fR cells were treated with a dosage range of STS (0–50 mM) for
6 hours. (a,d) Bioluminescent measurements of RLuc8 and fLuc
were acquired for each STS concentration after 6 hours (left axis).
The RLuc8:fLuc ratio was subsequently calculated for each STS
concentration (right axis). (b,e) A TUNEL assay for DNA
fragmentation was performed to provide a measure of cell death.
(c,f) Caspase 3/7 activity was determined using a Caspase 3/7 Glo
assay. In all studies (except TUNEL assays, which provide an
absolute measure of cell death), measurements were normalized to
values at 0 mM STS.
(TIF)
Figure S4 Measurements of the bioluminescent ratio
after the coding sequences of fLuc and RLuc8 were
interchanged, relative to the IRES sequence. HeLa-fR cells
were treated with PBS or 10 mM STS for 24 hours and
bioluminescent measurements of RLuc8 and fLuc were acquired.
The ratio RLuc8:fLuc was subsequently calculated.
(TIF)
Figure S5 Assessment of D-luciferin and coelenterazine
stability in the presence of intracellular species and
enzymes. Wild-type HeLa cells were treated either with STS or
PBS for 24 hours. Subsequently, both D-luciferin and coelenterazine
(inlysisbuffer– DualGlo)wereadded tothecellsandthiswasfollowed
by the addition of purified fLuc and RLuc8 proteins. Bioluminescent
measurements of fLuc and RLuc8 were acquired and normalized to
the mean of PBS-treated controls, in the absence of STS.
(TIF)
Figure S6 Schematic representing potential path-
ways for intracellular protein modification and/or
degradation.
(TIF)
Figure S7 Control assays to validate inhibitor effective-
ness. HeLa-fR cells were pretreated with either PBS (gray bars)
or indicated inhibitors (white bars) for 1 hour before the addition
of 10 mM STS. The PBS/Inhibitors and STS were then incubated
with the cells for an additional 24 hours. (a) Proteasome inhibitors
were assayed using Proteasome-Glo. (b) Protease inhibitors were
assayed using Calpain-Glo (Calpain Inhibitor III), CV-Cathepsin
B Detection Kit (Pepstatin A) or Caspase-Glo 3/7 (z-vad-fmk). (c)
O2
N- scavengers were assayed using DHE. (d)
NOH scavengers were
assayed using HPF. (e)H 2O2-related scavengers were assayed
using CM-H2DCFDA (catalase and allopurinol) or the Cox
Activity Assay Kit (aspirin). All measurements were normalized to
the mean measurements in the absence of the respective inhibitor.
Statistical significance between -inhibitor and +inhibitor is
indicated with a * (p,0.05) or ** (p,0.01).
(TIF)
Figure S8 Measurements of H2O2 in HeLa-fR cells
pretreated with superoxide scavengers prior to the
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(control), 10 mM Tiron, 10 mM TEMPOL, or 100 mM
MnTMPyp for 1 hour, followed by PBS (white bars) or 10 mM
STS (gray bars) for 24 hours. HeLa cells were then assayed for
H2O2 levels using CM-H2DCFDA. All measurements were
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